RevieweNeurologicalSci2022
Migraine in the workplace.
Review in eNeurologicalSci, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 47 citations in OpenAlex.
- Trial
- Effects of kinesiotaping combined with physical therapy in patients with migraine-associated neck pain: a randomized controlled study.BMC musculoskeletal disorders · 2025Trial
- Psychological interventions for migraine.Nature reviews. Neurology · 2026Review
- Impact of migraine on work productivity of healthcare providers at Kasr Al-Ainy Hospital.BMC neurology · 2026Article
- Central sensitization, work-related stress, and musculoskeletal pain symptoms in desk-based workers with and without migraine: a cross-sectional study.The journal of headache and pain · 2026Observational
- Integrated analysis of two randomized controlled trials of a digital therapeutic for episodic migraine prevention.NPJ digital medicine · 2026Article
- Characterizing migraine burden and treatment response using nationwide smartphone app-based data in Korea.The journal of headache and pain · 2026Article
- Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME (US) study.Headache · 2026Observational
- Migraine care in the digital era: social listening insights and neurologists' perspectives from Türkiye.Frontiers in digital health · 2026Article
- Chronic headache disorders as a threat to brain health among employees of a city office in the Tokyo metropolitan area.The journal of headache and pain · 2025Article
- Hallmarks of primary headache: part 3 - cluster headache.The journal of headache and pain · 2025Review
- Exploring the professional and personal impact of migraine: a cross-sectional study in Greece.Journal of oral & facial pain and headache · 2025Article
- Article
- Impact of Headache and Over-the-Counter Treatment on Pain and Functional and Cognitive Parameters: A Real-World Study across Three Geographies.Pain and therapy · 2025Article
- Real-world adherence to erenumab, rescue medication utilization, and work absenteeism for patients with migraine: Results from an outcomes-based agreement.Journal of managed care & specialty pharmacy · 2025Article
- The Impact of Migraine on the Whole Life Course of Patients: Results from the OVERCOME (Japan) 2nd Study.Neurology and therapy · 2025Article
- Healthcare Utilization, Costs, and Treatment Discontinuation in Adults with Episodic Migraine Initiating Galcanezumab Versus Rimegepant: A US Retrospective Claims Analysis.Advances in therapy · 2025Article
- Fitness-to-work considerations in the paradigmatic pain condition of headache disorder.The journal of headache and pain · 2025Review
- Unveiling the Public Economic Burden of Migraine in Argentina.Journal of health economics and outcomes research · 2025Article
- Hallmarks of primary headache: part 1 - migraine.The journal of headache and pain · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is prevalent, disabling, and peaks during people's peak productive years. The impact of migraine on people's professional lives, work productivity, and interpersonal relationships at work eventually affects everyone, has a significant detrimental effect on people with migraine, and a huge cost in terms of lost productivity. People with migraine want to work, so they do their best to work despite the varied migraine related and associated symptoms. Most of migraine-related productivity loss (89%) is due to presenteeism. People are less than half effective during a migraine attack due to the pain, migraine symptoms, attack unpredictability, migraine comorbidities, emotional impact, under-diagnosis and under-management, and the stigma. Migraine-related productivity loss may negatively affect people's career choice, job status and/or security, financial status, work relationships, mood, and confidence. Migraine is estimated to represent 16% of total US workforce presenteeism. Thankfully, there are ways to help support people with migraine in the workplace and increase their productivity such as: workplace migraine education programs, workplace migraine education and management programs, migraine-friendly work environment, migraine treatment optimization and advocacy. The example of the successful workplace migraine education and management program developed and run in collaboration between Fujitsu, the Japanase Headache Society, and the International Headache Society Global Patient Advocacy Coalition is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.